ArticleUpdates in surgery2026
Pure single-port robotic Roux-en-Y gastric bypass in a patient with metabolic syndrome: first worldwide report.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pure single-port robotic Roux-en-Y gastric bypass (SP-RYGB) remains rarely reported because of limited working space and the technical challenge of performing dual intracorporeal anastomoses through a single incision. We present a pure SP-RYGB performed through a 2.5-cm transumbilical incision without auxiliary ports in a patient with metabolic syndrome. A four-arm configuration enabled construction of a calibrated gastric pouch, stapled gastrojejunostomy, Roux limb jejunojejunostomy, and closure of mesenteric defects under stable three-dimensional visualization. The patient resumed oral fluids and ambulation 2 h after surgery and was discharged on postoperative day 2. At 2-month follow-up, total weight loss reached 16.6%, accompanied by normalization of blood pressure and fasting glucose, without postoperative complications. This technical note demonstrates preliminary feasibility of SP-RYGB and provides a reproducible stepwise description for further evaluation.
Indexed as
Identifiers
41806171What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.